Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23473144 | 0.85 | GLB1 (0.55) | GLB1DPP4GBA1 | |
| SCHEMBL15533438 | 0.84 | GLB1 (0.40) | GLB1GBA1 | |
| Ammonia Solution, Strong SCHEMBL9805948 | 0.83 | GLB1 (0.53) | GLB1DPP4GBA1 | |
| SCHEMBL14493190 | 0.81 | DPP4 (0.38) | GLB1DPP4GBA1 | |
| SCHEMBL20685653 | 0.81 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL26791035 | 0.81 | DPP4 (0.38) | GLB1DPP4GBA1 | |
| SCHEMBL23167590 | 0.81 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL23165638 | 0.81 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL23167577 | 0.81 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL4373139 | 0.81 | GLB1 (0.34) | GLB1DPP4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0494005-B1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | OREAL (FR) | 1997-02-05 | — | — | EP | claimed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-5360804-A | STABILITY | L'OREAL (FR) | 1994-11-01 | — | — | US | disclosed |
| US-4393065-A | INCREASED PRODUCTIVITY OF BY-PRODUCTS BY INCLUSION OF PYRIMIDINE COMPOUNDS | THE UPJOHN COMPANY (US) | 1983-07-12 | — | — | US | disclosed |
| US-4316901-A | Animal feed and process | THE UPJOHN COMPANY (US) | 1982-02-23 | — | — | US | disclosed |
| US-4315930-A | A DIAMINO-TRIAZINE-3-OXIDE | THE UPJOHN COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0042669-A2 | Compounds and compositions for use in animal feeds | THE UPJOHN COMPANY (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4308271-A | PYRIMIDINE OXIDE DERIVATIVES TO INCREASE PRODUCTION | THE UPJOHN COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4307093-A | INCREASING PRODUCTION USING OXATRIAZINES | THE UPJOHN COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4282228-A | Animal feed and process | THE UPJOHN COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | GLB1 532/4885DPP4 4788/4885GBA1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.